4:59 is 5AM’s hands-on internal effort to discover, incubate, and fund breakthrough science. We seek to partner alongside academics and entrepreneurs – often serving as an extension of the operating team – to establish proof-of-concept data that will enable a Series A Financing.
5AM Ventures Strategy primarily invests in private therapeutic companies. The funds are typically early-stage focused, with an emphasis on Series A companies.
5AM Opportunities Strategy invests in small and mid-cap public and later-stage private biotech and life science companies.
We’re a life science venture capital firm founded in 2002 and currently investing $450M from 5AM Ventures VII and $300M from 5AM Opportunities II.
Our focus is biopharmaceuticals, drug delivery technologies and life science instruments.
Our portfolio companies have over 40,000 patients enrolled across 450+ test sites in clinical trials.